| Literature DB >> 34102706 |
Linzhen Hu1, Shuying Tian1, Rongrong Wu1, Zhou Tong1, Wen Jiang1, Ping Hu1, Xueyang Xiao1, Xueke Zhang1, Hui Zhou1, Qingyi Tong2, Yuanyuan Lu3, Zhiyong Huang1,4, Yong Chen1, Yonghui Zhang2.
Abstract
Two novel alkaloids compounds together with fifteen know metabolites were identified from Aspergillus ochraceus. The stereochemistry features of the new molecules were determined via HRESIMS, NMR, ECD, and XRD analyses. Amongst these, compounds two compounds exhibited potential efficacy as anti-Parkinson's disease with the EC50 values of 2.30 and 2.45 μM, respectively. ADMET prediction showed that these compounds owned favorable drug-like characteristics and safe toxicity scores towards CNS drugs. Virtual screening analyses manifested that the compounds exhibited not only robust and reliable interactions to adenosine receptors A2A , but also higher binding selectivity to A2A receptors than to A1 and A3 receptors. Molecular dynamics simulation demonstrated the reliability of molecular docking results and the stability of the complexes obtained with the novel compounds and A2A receptors in natural environments. It is the first time that anti-PD lead compounds have been identified from Aspergillus ochraceus and targeting adenosine A2A receptors.Entities:
Keywords: Aspergillus ochraceus; Parkinson's disease; adenosine receptors; alkaloids; drug discovery; virtual screening
Mesh:
Substances:
Year: 2021 PMID: 34102706 PMCID: PMC8186885 DOI: 10.1002/open.202100022
Source DB: PubMed Journal: ChemistryOpen ISSN: 2191-1363 Impact factor: 2.630
Figure 1Structures of compounds 1–17 from Aspergillus ochraceus.
1H NMR (400 MHz) and 13C (100 MHz) Data for compounds 7 and 17 (δ in ppm, J in Hz).
|
No. |
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
|
1 |
|
|
|
159.6 |
|
2 |
|
166.8 |
6.84 m |
116.9 |
|
3 |
|
131.4 |
7.52 m |
127.1 |
|
4 |
7.76 dd (7.6, 1.5) |
128.8 |
|
120.7 |
|
5 |
7.55 m |
128.7 |
7.55 m |
127.1 |
|
6 |
7.64 m |
130.6 |
6.86 m |
116.9 |
|
7 |
7.60 br s |
129.0 |
|
|
|
8 |
|
133.3 |
|
166.4 |
|
10 |
|
160.9 |
7.21 s |
120.1 |
|
11 |
|
122.0 |
|
153.7 |
|
12 |
7.44 d (2.8) |
109.8 |
4.92 dd (13.4, 6.7) |
64.3 |
|
13 |
|
157.7 |
1.59 d (6.7) |
21.5 |
|
14 |
7.31 dd (8.8, 2.8) |
124.6 |
|
|
|
15 |
7.58 br s |
128.6 |
|
|
|
16 |
|
138.5 |
|
|
|
18 |
|
153.1 |
|
|
|
19 |
4.28 p (12.5, 6.5) |
49.3 |
|
|
|
20 |
1.50 d (6.7) |
14.9 | ||
[a] Record in DMSO‐d. [b] Record in CH3OH‐d 4.
Figure 2Key 2D NMR correlations of compounds 7 and 17.
Figure 3Experimental ECD spectra of 7 and 17, and calculated ECD spectra of 19R‐7, 19S‐7, and 12R‐17.
Figure 4X‐ray ORTEP drawing of 7 and 17.
Anti‐PD Activities of compounds 1–17 on SH‐SY5Y cells and MPP+‐induced SH‐SY5Y cells (μM).
|
Compounds |
CC50 [a] |
EC50 [b] |
SI[c] (CC50/EC50) |
|---|---|---|---|
|
|
152.70 |
80.21 |
1.90 |
|
|
82.15 |
35.71 |
2.30 |
|
|
99.54 |
38.75 |
2.57 |
|
|
67.57 |
46.18 |
1.46 |
|
|
75.21 |
37.67 |
2.00 |
|
|
70.17 |
49.53 |
1.42 |
|
|
80.45 |
10.77 |
7.47 |
|
|
56.61 |
5.44 |
10.41 |
|
|
57.35 |
7.39 |
7.76 |
|
|
45.59 |
9.97 |
4.57 |
|
|
39.21 |
5.31 |
7.38 |
|
|
49.55 |
6.01 |
8.24 |
|
|
30.45 |
2.98 |
10.22 |
|
|
81.93 |
2.30 |
35.62 |
|
|
83.68 |
2.45 |
34.16 |
|
|
46.37 |
7.39 |
6.27 |
|
|
103.05 |
17.84 |
5.77 |
|
Levodopa (LD) |
154.9 |
2.06 |
75.19 |
[a] 50 % cytotoxic concentration value. [b] 50 % effective concentration value. [c] Selectivity Index.
Figure 5Effects on SH‐SY5Y cells and MPP+ insult SH‐SY5Y cells viabilities of compounds 14 and 15 were evaluated using Levodopa (LD) as a positive control in vitro. Both values of CC50 and EC50 were calculated as mean values with standard deviations (n=3, P<0.05).
Prediction for the adsorption, distribution, metabolism, and excretion properties of compounds 7–17.
|
Compounds |
MW[a] |
AlogP[b] |
logD[c] |
HBD[d] |
PSA[e] |
Rotatable Bonds[f] |
Solubility Level[g] |
BBB Level[h] |
Absorption Level[i] |
|---|---|---|---|---|---|---|---|---|---|
|
|
307.3 |
1.75 |
1.75 |
2 |
82 |
0 |
3 |
3 |
0 |
|
|
291.3 |
1.99 |
1.99 |
1 |
61.77 |
0 |
2 |
3 |
0 |
|
|
307.3 |
1.75 |
1.75 |
2 |
82 |
0 |
3 |
3 |
0 |
|
|
264.3 |
2.99 |
3.21 |
2 |
62.05 |
2 |
2 |
2 |
0 |
|
|
447.5 |
1.47 |
1.47 |
2 |
87.74 |
0 |
2 |
3 |
0 |
|
|
447.5 |
1.47 |
1.47 |
2 |
87.74 |
0 |
2 |
3 |
0 |
|
|
461.2 |
2.62 |
2.62 |
2 |
83.66 |
1 |
2 |
3 |
0 |
|
|
445.5 |
2.72 |
2.72 |
2 |
91.5 |
0 |
1 |
3 |
0 |
|
|
431.5 |
3.16 |
3.16 |
2 |
74.43 |
0 |
1 |
2 |
0 |
|
|
449.5 |
2.11 |
2.11 |
2 |
87.74 |
4 |
2 |
3 |
0 |
|
|
205.2 |
1.37 |
1.35 |
2 |
66.49 |
2 |
4 |
3 |
0 |
Profiles of a CNS drug candidate: [a] Molecular weight: suggested limits, <500 D; preferred range, <450 D. [b] (ACD calculated) Logarithm of octanol/water partition coefficient: suggested limits, 2–5; preferred range, 2–4. [c] Logarithm of the octanol/water distribution coefficient (at a given pH 7.4): suggested limits, 2–5; preferred range, 2–4. [d] Hydrogen bond donors: suggested limits, 0–3; preferred range, 0–1. [e] Polar surface area: suggested limits, <90; preferred range, <70. [f] Suggested limits, 0–8. [g] Extremely low, 0; very low, 1; low, 2; good, 3. [h] Blood‐brain barrier: very high penetrant, 0; high, 1; medium, 2; low, 3; undefined, 4. [i] Human intestinal absorption level: good, 0; moderate, 1; poor, 2; very poor, 3.
Prediction for the toxicities of compounds 7–17.
|
Compounds |
Rat NTP[a] |
Mouse NTP[a] |
Ames mutagenicity[b] |
DTP[c] | ||
|---|---|---|---|---|---|---|
|
Male |
Female |
Male |
Female | |||
|
|
−3.22 |
−1.92 |
−2.29 |
−3.61 |
−3.19 |
−0.947 |
|
|
−0.933 |
−0.0252 |
−3.1 |
−1.5 |
−2.31 |
−3.08 |
|
|
−1.8 |
−0.175 |
−2.76 |
−4.34 |
−4.08 |
−1.54 |
|
|
2.41 |
1.11 |
−0.497 |
−0.217 |
9.96 |
−4.61 |
|
|
0.38 |
−8.28 |
−3.79 |
2.01 |
−9.39 |
1.13 |
|
|
0.38 |
−8.28 |
−3.79 |
2.01 |
−9.39 |
1.13 |
|
|
0.583 |
−7.4 |
−4.83 |
2.07 |
−7.66 |
1.99 |
|
|
0.708 |
−7.34 |
−4.99 |
2.29 |
−8.38 |
0.319 |
|
|
1.5 |
−8.77 |
−3.39 |
2.02 |
−10.7 |
0.332 |
|
|
−0.523 |
−11.3 |
−6.31 |
2.34 |
−23.2 |
−2.11 |
|
|
−0.752 |
−1.13 |
−1.68 |
−1.36 |
0.726 |
−1.71 |
[a] U.S. National Toxicology Program: noncarcinogen, NTP<0.3; carcinogen>0.8. [b] Nonmutagen, <0.3; mutagen, >0.8. [c] Developmental toxicity potential: nontoxic, DTP<0.3; toxic, >0.8.
Details of LibDockScore, CDOCKER Interaction Energy (kcal/mol), binding energies (kcal/mol), and inhibition constant (Ki) of compounds 7–17.
|
Compounds |
LibDockScore |
CDOCKER Interaction Energy |
A2AR (PDB code: 3EML) |
A1R (PDB code: 5 N2S) |
A3R (PDB code: 1OEA) | |||
|---|---|---|---|---|---|---|---|---|
|
Binding Energy |
Inhibition Constant |
Binding Energy |
Inhibition Constant |
Binding Energy |
Inhibition Constant | |||
|
|
104.66 |
−40.15 |
−8.00 |
1.36 μ |
−7.59 |
2.75 μ |
−6.78 |
10.69 μ |
|
|
100.80 |
−36.64 |
−7.79 |
1.94 μ |
−7.77 |
2.02 μ |
−10.02 |
45.59 n |
|
|
107.02 |
−40.82 |
−8.05 |
1.25 μ |
−7.42 |
3.66 μ |
−8.83 |
337.34 nM |
|
|
98.06 |
−43.66 |
−7.71 |
2.21 μ |
−7.30 |
4.48 μ |
−7.74 |
2.11 μM |
|
|
115.27 |
−42.37 |
−8.97 |
268.03 n |
−7.98 |
1.42 μ |
−7.60 |
2.67 μM |
|
|
113.11 |
−43.84 |
−8.92 |
287.03 n |
−8.14 |
1.08 μ |
−8.05 |
1.25 μM |
|
|
116.75 |
−45.85 |
−9.00 |
251.78 n |
−9.40 |
128.28 n |
−6.17 |
30.09 μM |
|
|
126.00 |
−45.93 |
−10.27 |
29.61 n |
−6.20 |
28.46 μ |
−7.23 |
5.02 μM |
|
|
117.97 |
−42.88 |
−9.57 |
96.89 n |
−8.15 |
1.06 μ |
−8.54 |
554.08 nM |
|
|
122.45 |
−45.29 |
−7.36 |
4.04 μ |
−7.96 |
1.46 μ |
−7.25 |
4.81 μM |
|
|
79.32 |
−31.47 |
−5.95 |
43.60 μ |
−5.72 |
64.55 μ |
−6.69 |
12.38 μM |
|
istradefylline |
121.74 |
−51.76 |
−7.83 |
1.82 μ |
−7.50 |
3.71 μ |
−7.65 |
2.45 μM |
Figure 6Left: the change of RMSD of backbone atoms in molecular dynamics simulation; Right: the change of RMSF of amino acid residues in molecular dynamics simulation.
Figure 7Residue interaction histograms of non‐bond interactions of 14‐A2AR complex. A: Residues with favorable interactions; B: Residues with unfavorable interactions; C: Residues with hydrogen bond interactions; D: Residues with hydrophobic interactions.
Figure 8Visual graphic interactions of molecular docking between 14 and A2AR. Left: the whole drawing of 14‐A2AR; Right: the amplified drawing of 14 docking in pocket sites of A2AR (The above: 3D graphic; The Below: 2D graphic).
Figure 9A) MS spectrum of methanol extract of A. ochraceus cultivated in PDA‐Control; B) MS spectrum of methanol extract of A. ochraceus cultivated in PDA‐Test.